A 24-year review on the epidemiology and control of measles in Singapore, 1981-2004

Southeast Asian Journal of Tropical Medicine and Public Health

Volumn 37, Issue 1, 2006, Pages 96-101

  Ong, Gary ^a   Hoon, Heng Bee ^b   Ong, Adrian ^a,c   Chua, Lian Tee ^a   Kai, Chew Suok ^a   Tai, Goh Kee ^a  

^a MINISTRY OF HEALTH   (Singapore)

^b NATIONAL HEALTHCARE GROUP   (Singapore)

^c TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33744472185     PISSN: 01251562     EISSN: 26975718     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Chuang SK, Lau YL, Lim WL, Chow CB, Tsang T, Tse LY. Mass measles immunization campaign: experience in the Hong Kong Special Administrative Region of China. Bull World Health Organ 2002; 80: 585-91.
2. Committee on Epidemic Diseases. Seroepidemiology of measles, mumps and rubella. Epidemiol News Bull 1991; 17: 25-6.
3. Committee on Epidemic Diseases. Prevalence of antibodies to measles, mumps and rubella in Singapore. Epidemiol News Bull 1995; 21: 25-9.
4. Committee on Epidemic Diseases. Changing epidemiology of measles in Singapore. Epidemiol News Bull 1997; 23: 31-3.
5. Committee on Epidemic Diseases. Progress in the elimination of measles from Singapore. Epidemiol News Bull 2003; 29: 1-5.
6. Duclos P, Paulsen E. Measles elimination in Canada. Can J Public Health 1995; 86: 370.
7. Duclos R Redd SC, Varughese P, Hersh BS. Measles in adults in Canada and United States: implications for measles elimination and eradication. Int J Epidemiol 1999; 28: 141-6.
8. Goh DLM, Chew FT, Kor SH, Lee BW. Resurgence of measles in Singapore: Profile of hospital cases. J Paediatr Child Health 1999; 35: 493-6.
9. Goh KT. Epidemiological surveillance of communicable diseases in Singapore. Tokyo: Southeast Asian Medical Information Center/International Medical Foundation of Japan, 1983: 177-9.
10. Goh KT. Resurgence of mumps in Singapore caused by the Rubini mumps virus vaccine strain. Lancet 1999; 354: 1355-6.
11. Hutchins SS, Papania MJ, Amler R, et al. Evaluation of the measles clinical case definition. J Infect Dis 2004; 189 (suppl 1): S153-9.
12. Ministry of the Environment, Quarantine and Epidemiology Department. Epidemiological surveys. Commun Dis Surv Singapore 1999; 8: 3-4.
13. Oh HML, Lateef F, Chew SK, Doraisingham S. Descriptive profile and the immune status of some hospitalized patients with measles. Ann Acad Med Singapore 1995; 24: 373-5.
14. Ong G, Goh KT, Ma S, Chew SK. Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in a Asian population. J Infect 2005; 51: 294-8.
15. Orenstein WA, Bernier RH, Dondero TJ, et al. Field evaluation of vaccine efficacy. Bull World Health Organ 1985; 63: 1055-68.
16. Pelletier L, Chung P, Duclos P, et al. A benefit-cost analysis of two-dose measles immunization in Canada. Vaccine 1998; 9: 989-96.
17. World Health Organization (WHO). Measles surveillance. Wkly Epidemiol Rec 1979: 54: 217.
18. World Health Organization. WHO recommended strategies for the prevention and control of communicable diseases. Geneva: World Health Organization, 2001: 112.
19. World Health Organization; United Nations Children's Fund (UNICEF). Measles - Mortality reduction and regional elimination. Strategic Plan 2001-2005. Geneva: World Health Organization, 2001.
20. World Health Organization Regional Office for the Western Pacific. Western Pacific Regional Plan of Action for Mealses Elimination. Manila: World Health Organization, 2003.
21. World Health Organization Regional Office for the Western Pacific. Measles Bull 2004; 3.